Akshay Vaishnaw

Alnylam Pharmaceuticals (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

43h-index13.6kcitations90works163.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Amyloidosis: Diagnosis, Treatment, Outcomes(22), RNA Interference and Gene Delivery(21), Respiratory viral infections research(10), Advanced biosensing and bioanalysis techniques(8), RNA modifications and cancer(8)

Publications89 total

RNA interference in the era of nucleic acid therapeutics
Nature Biotechnology·2024· 163 cited
Data from First-in-Humans Trial of an RNA Interference Therapeutic Targeting VEGF and KSP in Cancer Patients with Liver Involvement
2023Open Access
Supplementary Tables from First-in-Humans Trial of an RNA Interference Therapeutic Targeting VEGF and KSP in Cancer Patients with Liver Involvement
2023Open Access
Supplementary Tables from First-in-Humans Trial of an RNA Interference Therapeutic Targeting VEGF and KSP in Cancer Patients with Liver Involvement
2023Open Access
Data from First-in-Humans Trial of an RNA Interference Therapeutic Targeting VEGF and KSP in Cancer Patients with Liver Involvement
2023Open Access
Supplementary Methods and Legends from First-in-Humans Trial of an RNA Interference Therapeutic Targeting VEGF and KSP in Cancer Patients with Liver Involvement
2023Open Access
Supplementary Methods and Legends from First-in-Humans Trial of an RNA Interference Therapeutic Targeting VEGF and KSP in Cancer Patients with Liver Involvement
2023Open Access
Supplementary Figures from First-in-Humans Trial of an RNA Interference Therapeutic Targeting VEGF and KSP in Cancer Patients with Liver Involvement
2023Open Access
Supplementary Figures from First-in-Humans Trial of an RNA Interference Therapeutic Targeting VEGF and KSP in Cancer Patients with Liver Involvement
2023Open Access
Rare loss of function variants in the hepatokine gene INHBE protect from abdominal obesity
Nature Communications·2022· 49 citedOpen Access
The Nonclinical Disposition and Pharmacokinetic/Pharmacodynamic Properties of N-Acetylgalactosamine–Conjugated Small Interfering RNA Are Highly Predictable and Build Confidence in Translation to Human
Drug Metabolism and Disposition·2021· 97 citedOpen Access
Association of the transthyretin variant V122I with polyneuropathy among individuals of African ancestry
Scientific Reports·2021· 28 citedOpen Access
Phase 1/2 Study of Lumasiran for Treatment of Primary Hyperoxaluria Type 1
Clinical Journal of the American Society of Nephrology·2021· 78 citedOpen Access
Neurofilament Light Chain (NfL) as a Potential Biomarker of Treatment Response in Hereditary Transthyretin-Mediated Amyloidosis: Data from the Patisiran Global OLE Study (1291)
Neurology·2021· 1 cited
Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1
New England Journal of Medicine·2021· 471 citedOpen Access
Neurofilament Light Chain (NfL) as a Potential Biomarker of Treatment Response in Hereditary TransthyretinMediated (hATTR) Amyloidosis: Patisiran Global OLE Study
2021· 1 citedOpen Access
Abstract 14387: Dose-Related Reductions in Blood Pressure With a RNA Interference (RNAi) Therapeutic Targeting Angiotensinogen in Hypertensive Patients: Interim Results From a First-In-Human Phase 1 Study of ALN-AGT01
Circulation·2020· 21 cited
Association of the transthyretin variant V122I with polyneuropathy among individuals of African descent
2020· 1 citedOpen Access
The V122I mutation in hereditary transthyretin-mediated amyloidosis is significantly associated with an increased incidence of polyneuropathy
European Heart Journal·2020Open Access
Neurofilament Light Chain as a Biomarker of Hereditary Transthyretin-Mediated Amyloidosis
Neurology·2020· 95 citedOpen Access
page 1 of 5Next →

Frequent Co-authors

Jared Gollob(14), Kevin Fitzgerald(11), Pushkal Garg(10), Verena Karsten(9), Jeffrey Cehelsky(8), Rachel Meyers(8), Saraswathy V. Nochur(7), Amy Simon(7), John P. DeVincenzo(7), Marianne T. Sweetser(6), Jamie Harrop(6), Brian R. Bettencourt(6), Renta Hutabarat(6), Keith B. Elkon(6), David Adams(5), Philip N. Hawkins(5), Valerie A. Clausen(5), Arnt V. Kristen(4), Ole B. Suhr(4), Joseph Chiesa(4)